LILLY ZYPREXA SHARE OF NEW ANTIPSYCHOTIC SCRIPTS INCREASES TO 12.9% IN JUNE; EVISTA PRIORITY REVIEW STATUS COULD GIVE LILLY A LATE 1997 APPROVAL
Executive Summary
Lilly's anti-psychotic Zyprexa (olanzapine) has captured almost 13% of new prescriptions through June, the company reported July 23. Zyprexa sales reached $156 mil. for the second quarter, the product's third quarter on the market. The product is tracking to reach $500 mil. in sales during its first 12 months of availability. Its market share at the end of June was 12.9%, up from 6% in January.